Facebook Linkedin Twitter
Inside Precision Medicine Burn Rubber: Superluminal Medicines Gets $120M to Take GPCR Drugs to Clinic

Membrane proteins

Superluminal Medicines
Informatics

Burn Rubber: Superluminal Medicines Gets $120M to Take GPCR Drugs to Clinic

Jonathan D. Grinstein, PhD
0
cancer development
Molecular Dx

Scientists Discover Cancer Protein Enhancing Anti-Tumoral Immune Response

0
T-cells' background, T cells
News & Features

Mechanism Revealed of How Gamma Delta T Cells Recognize Cancer

0
Nutritionist calculating body mass index of a woman for obesity treatment in a clinic room. Both are women with dark hair and light skin and are sitting opposite each other next to a computer on a table.
News & Features

Novo Nordisk Acquires Obesity Drug Developer Inversago for up to $1.075B

0
Opioid pain medication
News & Features

New Target for Addiction-Free Pain Treatment Found

0
Abstract Molecular structure
Molecular Dx

Liquid Biopsy: How to Embrace Perfection?

0
Man and DNA
News & Features

Gene Responsible for Group of Rare Immune Diseases Potentially Identified

0
Biocept will evaluate the clinical utility and cost effectiveness of using Biocept's Target Selector testing in patients diagnosed with non-small cell lung cancer (NSCLC)
Molecular Dx

Biocept to Study Clinical Utility, Cost Effectiveness of Assays in NSCLC Patients

0

Related Content

Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.
Inside Precision Medicine